We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes".
- Authors
Facchin, Sonia; Buda, Andrea; Savarino, Edoardo
- Abstract
Keywords: 16S metabarcoding; Gut Inflammation; inflammatory bowel disease; prebiotics; SCFA EN 16S metabarcoding Gut Inflammation inflammatory bowel disease prebiotics SCFA 1 2 2 12/31/20 20210101 NES 210101 We thank Sitkin et al. for their interest on our study and their valuable comments.1 The authors speculated that the microbiota changes observed in our study by the addition of butyrate to conventional therapy in patients with IBD could be explained by the activation of epithelial peroxisome proliferator-activated receptor- (PPAR- ) signaling, the generation of Treg cells in the colonic lamina propria, the restore of Th17/Treg balance by inhibiting histone deacetylase, and the enhancement of epithelial barrier function and intestinal homeostasis through hypoxia-inducible factor stabilization. 16S metabarcoding, Gut Inflammation, inflammatory bowel disease, prebiotics, SCFA.
- Subjects
INFLAMMATORY bowel diseases; BUTYRATES; GUT microbiome; ORAL microbiology; REACTIVE nitrogen species; SODIUM butyrate; PEROXISOME proliferator-activated receptors
- Publication
Neurogastroenterology & Motility, 2021, Vol 33, Issue 1, p1
- ISSN
1350-1925
- Publication type
Article
- DOI
10.1111/nmo.14054